Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Egetis Therapeutics increases revenue and prepares US launch of Emcitate

Egetis Therapeutics reported a currency-adjusted revenue increase of 23% to SEK 17.4m in the second quarter and ended the quarter with SEK 378m in cash after a SEK 350m capital raise. Operating loss widened to SEK 109.3m as the company invested in the US approval process, building its sales organization and launch preparations. The FDA has accepted the approval application for Emcitate and set a PDUFA date of 28 September; if approved, a US launch is planned for Q4, prompting a positive reaction in the stock. » Altro su de.investing.com
Egetis Therapeutics could receive FDA priority review voucher if approved

Egetis Therapeutics would qualify for a Priority Review Voucher under the FDA’s Rare Pediatric Disease Priority Review Program if approved; the program has been extended through 2029. Such vouchers accelerate future approval processes or can be sold to other pharma companies, making them a valuable asset for the company. A voucher would strategically help Egetis in the development and commercialization of its therapies for rare pediatric diseases. » Altro su de.investing.com
Egetis Therapeutics falls despite positive Triac data after Q3 results

Egetis Therapeutics reported Q3 2025 revenue rising to SEK 17.4m (Q3 2024: SEK 9.4m) and an improved but still negative operating loss for the year of SEK -219.6m. The ReTRIEVE study showed positive, statistically significant results and Triac received Breakthrough Therapy Designation. After the earnings call the stock fell 4.49% to USD 5.11; the company bolstered liquidity via a rights issue of SEK 172m. Egetis plans to submit a rolling NDA for MCT8 deficiency in December 2025, with expected FDA review in Q3 2026 and target U.S. market launch in H2 2026. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Egetis Therapeutics ha registrato ricavi pari a 1,57 Mln € e un utile netto di -9,83 Mln €

(EUR)	giu 2026	YoY
Ricavi	1,57 Mln	20,66%
Utile lordo	324,85K	141,31%
Utile netto	-9,83 Mln	41,10%
EBITDA	-8,7 Mln	30,10%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	336,85 Mln €
Numero di azioni	464,95 Mln
Massimo/minimo a 52 settimane	0,73 € - 0,33 €
Dividendi	No
Beta	0,78
Rapporto P/E	-7,96
Rapporto PEG	9,34
Rapporto P/B	7,50
Rapporto P/S	56,55

Profilo aziendale

Egetis Therapeutics AB (publ), ein Unternehmen der pharmazeutischen Arzneimittelentwicklung, konzentriert sich auf Projekte in der späten Entwicklungsphase zur Behandlung schwerer seltener Nischenkrankheiten mit ungedecktem medizinischem Bedarf im Bereich der Orphan Drugs. Die Produktpipeline des Unternehmens umfasst Aladote, ein Medikament zur Verringerung des Risikos akuter Leberschäden im Zusammenhang mit Acetaminophen/Paracetamol-Vergiftungen, das sich in der klinischen Phase IIb/III befindet, sowie Emcitate, ein Medikament zur Behandlung des MCT8-Mangels, einer seltenen angeborenen Störung der Schilddrüsenhormon-Signalübertragung, das sich in der klinischen Phase IIb/III befindet. Das Unternehmen war früher als PledPharma AB (publ) bekannt und änderte im Dezember 2020 seinen Namen in Egetis Therapeutics AB (publ). Egetis Therapeutics AB (publ) wurde im Jahr 2006 gegründet und hat seinen Sitz in Stockholm, Schweden.